Table 2.
Ingenuity Pathway Analysis (IPA) top canonical pathways
| Ingenuity canonical pathwaysa | −log(B‐H p‐value) | p‐value | Ratio | Differentially expressed genesb |
|---|---|---|---|---|
| Intrinsic prothrombin activation pathway | 5.81 | 1.549E‐06 | 0.0976 | COL1A2, COL1A1, F13A1, COL3A1 |
| Complement system | 4.34 | 4.571E‐05 | 0.0833 | C1R, C7, CFI |
| Atherosclerosis signaling | 4.34 | 4.571E‐05 | 0.0323 | COL1A2, COL1A1, LYZ, COL3A1 |
| GP6 signaling pathway | 2.79 | 1.622E‐03 | 0.0229 | COL1A2, COL1A1, COL3A1 |
| Hepatic fibrosis/hepatic stellate cell activation | 2.53 | 2.951E‐03 | 0.0164 | COL1A2, COL1A1, COL3A1 |
| Dendritic cell maturation | 2.53 | 2.951E‐03 | 0.0162 | COL1A2, COL1A1, COL3A1 |
| Neuroprotective role of THOP1 in Alzheimer's disease | 1.73 | 1.862E‐02 | 0.0179 | C1R, SERPINA3 |
| Acute phase response signaling | 1.45 | 3.548E‐02 | 0.0118 | C1R, SERPINA3 |
| Extrinsic prothrombin activation pathway | 1.37 | 4.266E‐02 | 0.0625 | F13A1 |
a
Significant pathways after Benjamini‐Hochberg multiple testing correction.
b
Derived from an input of n = 19 differentially expressed genes with FPKM ≥5.